Although the aforementioned data suggest that inhibition of NLRP3 using the small molecule NLRP3 inhibitor MCC950 is a safe and effective treatment of VIPN in rodents, the effects of NLRP3 inhibition on cancer progression and chemotherapy efficacy are unknown. Here, NLRP3 is linked to cancer.